01 Oct 2023
en
Crystal Pharmatech is pleased to announce the appointment of Dr. LianFeng Huang as Chief Scientist.
Dr. Huang is an accomplished R&D leader with over 30 years of experience in successfully leading pharmaceutical sciences departments and CMC project teams. She has enabled over 40 drug candidate selections, established and led the discovery support function and department for J&J, and championed several innovation initiatives such as pediatric formulation development, salt and crystal form screening and selection platforms, material science working group. Dr. Huang’s technical expertise includes drug candidate CMC developability assessment, solid-state form/salt screen and selection, pre-formulation and formulation development for poorly soluble drugs, discovery support and biopharmaceutical evaluations.
Before joining Crystal Pharmatech, Dr. Huang served as the Scientific Director of Material Science and Engineering at Bristol-Myers Squibb (BMS), a member of the Scientific Advisory Board in Pharmaceutical Development, and an expert in this field. From 2010-2019, she was the Principal Investigator/Director at Celgene Corporation. Between 2002-2010, Dr. Huang was the Head of Pharmaceutical Sciences and was responsible for solid-state form/salt screening and selection for all development compounds in Johnson & Johnson US(J&J), as well as first-in-human (FIH) formulation development to support phase I and phase IIa studies. From 1993-2002, she was a technical backbone in pre-formulation research at GlaxoSmithKline (GSK).
Dr. Huang owns over 50 granted patents and more than 150 patent applications and has published numerous academic papers in leading journals like Mol. Pharmaceutics and Adv. Drug Delivery Rev. She has been frequently invited to speak at international conferences in the USA and China, including AAPS and the AAPS/Chinese Pharmaceutical Association joint conference.
Dr. Lianfeng Huang expressed great enthusiasm about joining Crystal Pharmatech, stating: "Crystal Pharmatech's technical capability and business level in polymorphism and formulation are second to none, with a great reputation in the industry. Many of the companies I have worked with in the past and many old friends are loyal customers. I am very excited to join and work with an outstanding team to promote the development of innovative drugs and provide high-quality solutions for clients."
Shannon Bi, COO of Crystal Pharmatech, warmly welcomed Dr. Huang's joining: "Dr. Huang is a highly experienced technical expert in the field of solid-state research. Her rich experience and professional knowledge will bring new vitality and innovation to us. Under Dr. Huang's leadership and guidance, our solid-state research and pre-formulation business will achieve greater breakthroughs and development."
Dr. Alex Chen, co-founder, Chairman, and CEO of Crystal Pharmatech, looks forward to Dr. Lianfeng Huang's joining: "As a CRO/CDMO focused on providing world-leading solid-state research, formulation development and manufacturing services for global innovative drug companies, Crystal Pharmatech is committed to offering the optimal polymorph and best formulation for our clients. Dr. Huang's technical expertise covers key areas, such as salt/polymorph screening and selection, pre-formulation study, and formulation development for poorly soluble drugs. I have always admired and respected Dr. Huang’s academic achievements and scientific strength, often studying her published works. Her joining will inject strong technical strength and practical experience into Crystal Pharmatech, further enhancing our competitiveness in drug development. Together, we will drive innovation and development in the field of drug research and development, committed to helping innovative drug clients develop more competitive new drugs."
